brauman50, I was under the impression it was a savings of $400M.
You are right about the funding gap. I owned FCX back in 2001 when nothing but FCX's debt load for the Grasberg gold/copper mine was all anyone would highlight. Copper prices ran up, and FCX made so much money they bought Phelps Dodge too. The higher NG prices are making the CHK debt load an affectation of the bear story.
I can't find the article. Where is it published? Is it just some comments on Twitter?
rumorthegreat, that was a great recommendation. I went over to agoracom , and it was great to read real comments from investors in mnkd and some trial users of afrezza. Thanks for the heads-up.
Perhaps the option player is reacting to the likely repeal of the medical device tax from companies such as THOR.
Looks like I may be the only one to see the 3000 May 38, 29, and 40 calls bought in the opening few minutes Friday, March 28. There were other call strikes heavily bought for April, but not nearly as many. I wonder what some big player knows or thinks he knows. The May options expire several weeks after the next earnings release.
I read the article. It is a waste of time and money. The pittance of $40M Obama wants to spend on NG is just for studying more ways to make it safe, which is code for more ways to regulate it. The other money is mostly to promote use of electricity for vehicles and stuff. I read more than the headlines, which were misleading.
Yes.
I admit I have not read the HTWR conf call from yesterday, so I wonder if HTWR said anything that could have caused THOR's stock price to move down today. All I have seen so far is Northland said HTWR expectations look overly optimistic, and put a price target of $60 on HTWR. I see THOR is down a bit today, and I wonder if HTWR said anything to set that in motion.
A silcon power amp and saw filters will is no solution for any world phone. Actually it would only be sort of a point solution for the lowest end LTE phones. I think this preannouncement from QCOM looks like an attempt at a low quality reference design for vendors who are having trouble with their front end engineers who need some help getting something to function to some extent.
prof4, thanks for the further explanation. I do hope something like the HM3 could eliminate the need for heart transplants sometime in the future. Thanks for clearing up the fog where I read about it. It is an interesting projection.
Why are you mentioning graphene and FARO in a post? Graphene is still very much an R&D material at the university Ph.D. level and some big corporate labs level. I am prepared to be educated, but would you give me some direction you think FARO could go with graphene in the next few years?
FARO is doing work with laser measuring device products, and I would be concerned if FARO is budgeting spending on basic research with graphene at this time. Maybe I am just ignorant of the progress with graphene, but I am willing and anxious to be educated.
I thought I read a post, I think from you, the other day that stated the THOR CEO said the HeartMate III could make heart transplants obsolete (or something like that). I searched the latest THOR call transcript, but I could not find it there. Did you actually write the above in a post? If yes, where did the CEO say that? Thanks, and sorry if my memory was just bad about reading this on this board.
Don't be silly. No one is talking about buying Heartware for about three years now. I also sold all my THOR long ago in the 40s after the FDA Destination, but I continued and continue to sell puts between 30 and 35 each month or quarter. I pick up lots of free money that way, and so far I have not been exercised. Should I be exercised, I am confident THOR will keep moving up above whatever strike price I selected for that month/quarter. Until THOR breaks above about 41, I am content to make money on naked THOR puts. You should have been doing this too.
It appears to me the Northland analyst really messed up this time. The letter which the professor included in a post to this THOR board earlier today explains the request, and it is linked in this document below too. All the Det Norske Veritas letter does is ask Medicare guys (CMS) to allow Veritas to approve VAD hospitals too. The letter goes over all the experience, etc., Veritas has already demonstrated. If you want to read all about this, google or bing the title of the CMS bulletin below. The action is to ask for public comment over 30 days. That's it, and Northland seems not to have understood it. That is my premise.
National Coverage Analysis (NCA) Tracking Sheet for Ventricular Assist Devices for Bridge-to-Transplant and Destination Therapy (CAG-00432R)
THOR needed to close a gap up between 35.64 and 35.75 from November 20 and 21. Northland provided that technical indicator need to close the gap on the open today. The gap is now closed, and that makes moving higher less stressful for technical traders.
I have not listened to the conf call yet. Did the CEO actually reference testing of the HeartMate III on the call?
gar4one, I just wondered if the QCOM conference call had anything to do with BRCM's situation with LTE design wins. I have no idea, but that was my guess as I saw the price breaking today.
The Thales battery controller has a lot of semiconductor memory as well as logic chips to run it. Soft errors in memory chips that could lead to hard errors in the controller, could lead to logic errors or a short circuit that could start a fire with that much power being controlled. Neutrons and protons in the atmosphere at 30,000 or 40,000 feet are very prevalent up there, and they can cause soft errors in high tech chips. If they find problems with the controller, I hope they look at this potential problem. It is Very hard to simulate such soft errors in memory or logic at normal earth altitudes.
french stamps, it is for propane and not methane (natural gas).